文献速递血液净化与透析水电解质与酸碱

维持性血透患者中SSRI类药物的比较心脏安全性

Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.
PubMed 文献 · J Am Soc Nephrol · 2019-03-18

本研究基于美国肾脏数据系统2007-2014年医保受益人数据,采用新用药者设计比较维持性血透患者启动高QT延长潜力SSRI(西酞普兰、艾司西酞普兰)与低QT延长潜力SSRI(氟西汀、氟伏沙明、帕罗西汀、舍曲林)后1年心脏性猝死风险。结果显示高QT延长潜力SSRI组心脏性猝死风险更高(调整HR 1.18,95%CI 1.05-1.31),在老年人、女性、传导障碍患者及合用其他非SSRI类QT延长药物者中更明显。

要点

  • 血透患者启动高QT延长潜力SSRI后1年心脏性猝死风险较低QT延长潜力SSRI升高18%。
  • 老年人、女性、传导障碍及合用其他QT延长药物者风险更突出。
  • 血透患者处方SSRI时应考虑不同药物QT延长潜力的差异。

核心结论

  • 在维持性血透患者中,启动高QT延长潜力SSRI较低QT延长潜力SSRI与更高的1年心脏性猝死风险相关(调整HR 1.18,95%CI 1.05-1.31)。

研究设计与样本

  • 回顾性队列研究,使用美国肾脏数据系统2007-2014年医保受益人数据,采用新用药者设计。
  • 比较启动高QT延长潜力SSRI(西酞普兰、艾司西酞普兰)与低QT延长潜力SSRI(氟西汀、氟伏沙明、帕罗西汀、舍曲林)的血透患者。
  • 高QT延长潜力组30,932例(47.1%),低QT延长潜力组34,722例(52.9%)。
  • 采用逆概率治疗加权生存模型估计调整风险比,非心脏性猝死作为竞争事件。

主要发现

  • 高QT延长潜力SSRI组较低QT延长潜力SSRI组1年心脏性猝死风险更高(调整HR 1.18,95%CI 1.05-1.31)。
  • 该关联在老年人、女性、传导障碍患者及合用其他非SSRI类QT延长药物者中更明显。

临床怎么用

  • 血透患者需用SSRI时,可优先考虑低QT延长潜力药物(氟西汀、氟伏沙明、帕罗西汀、舍曲林)。
  • 对老年人、女性、传导障碍及合用其他QT延长药物者,应加强心电图监测与风险权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Individuals receiving maintenance hemodialysis may be particularly susceptible to the lethal cardiac consequences of drug-induced QT prolongation because they have a substantial cardiovascular disease burden and high level of polypharmacy, as well as recurrent exposure to electrolyte shifts during dialysis. Electrophysiologic data indicate that among the selective serotonin reuptake inhibitors (SSRIs), citalopram and escitalopram prolong the QT interval to the greatest extent. However, the relative cardiac safety of SSRIs in the hemodialysis population is unknown. METHODS: In this retrospective cohort study, we used data from a cohort of Medicare beneficiaries receiving hemodialysis included in the US Renal Data System registry (2007-2014). We used a new-user design to compare the 1-year risk of sudden cardiac death among hemodialysis patients initiating SSRIs with a higher potential for prolonging the QT interval (citalopram, escitalopram) versus the risk among those initiating SSRIs with lower QT-prolonging potential (fluoxetine, fluvoxamine, paroxetine, sertraline). We estimated adjusted hazard ratios using inverse probability of treatment weighted survival models. Nonsudden cardiac death was treated as a competing event. RESULTS: The study included 30,932 (47.1%) hemodialysis patients who initiated SSRIs with higher QT-prolonging potential and 34,722 (52.9%) who initiated SSRIs with lower QT-prolonging potential. Initiation of an SSRI with higher versus lower QT-prolonging potential was associated with higher risk of sudden cardiac death (adjusted hazard ratio, 1.18; 95% confidence interval, 1.05 to 1.31). This association was more pronounced among elderly individuals, females, patients with conduction disorders, and those treated with other non-SSRI QT-prolonging medications. CONCLUSIONS: The heterogeneous QT-prolonging potential of SSRIs may differentially affect cardiac outcomes in the hemodialysis population.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Assimon MM, Brookhart MA, Flythe JE, et al. Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis. J Am Soc Nephrol. 2019. PMID: 30885935. doi:10.1681/ASN.2018101032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。